abacavir 300 mg

1 INDICATIONS AND USAGE Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Abacavir tablets, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 )

Major Pharmaceuticals

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] toxicity to various agents` `[3] off label use` `[4] completed suicide` `[5] nausea` `[6] drug abuse` `[7] fatigue` `[8] headache` `[9] pain` `[10] drug interaction`

3 months ago

OVAL YELLOW D 88

3 months ago

D 88 OVAL YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING

ABACAVIR tablets USP, containing

ABACAVIR sulfate equivalent to 300 mg

ABACAVIR, are yellow colored, biconvex, capsule shaped, coated tablet, debossed with ‘D’ and ‘88’ on either side of the score line on one side and plain with a score line on other side. They are packaged as follows: Cartons of 30 tablets (10 tablets per blister card x 3), NDC 0904-6874-04 Cartons of 50 tablets (10 tablets per blister card x 5), NDC 0904-6874-06 Store at 20° to 25 ° C (68° to 77 ° F); excursions permitted to 15 ° to 30 ° C (59 ° to 86 ° F) [ see USP Controlled Room Temperature ] .

More pills like OVAL D 88

Related Pills

abacavir tablet film coated

major pharmaceuticals

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site